This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singhal, A. K. Articles by Hakomori, S. Search for Related Content PubMed PubMed Citation Articles by Singhal, A. K. Articles by Hakomori, S.

Profiles of Lewis^x-containing Glycoproteins and Glycolipids in Sera of Patients with Adenocarcinoma¹

The Biomembrane Institute and University of Washington, Seattle, Washington 98119 [A. K. S., E. N., S. N., L. S., M. R. S., H. C., S. H.], and the Department of Clinical Chemistry, Aarhus County Hospital [T. F. Ø.], Aarhus, Denmark

Oligosaccharides with Le^x determinant (Galß14[Fuc13]GlcNAc) are accumulated in large quantities in various adenocarcinomas. Monoclonal antibodies recognizing mono-, di-, or trimeric Le^x showed a preferential staining of specific stages of human fetal tissues and various human adenocarcinomas. Thus, these carbohydrate epitopes are typical of oncodevelopmental antigens. The present study investigated the presence of Le^x epitope in sera of normal individuals and cancer patients, utilizing two high-affinity monoclonal antibodies, SH1 and SH2, directed to mono- and dimeric Le^x structures, respectively. The Le^x antigen in serum was eluted in the void volume fraction of a gel filtration column, determined by using monoclonal antibody SH1, and found to be carried on a glycoprotein with a molecular weight of approximately 200,000. The Le^x antigen was present in the void volume fraction of the majority (85%) of sera from adenocarcinoma patients. Although the Le^x epitope was also detected in a smaller proportion (33%) of normal sera, its levels were significantly lower than in cancer sera. Le^x antigen was also detected in serum glycolipid fraction; however, no significant differences were observed in normal and cancer sera. A double determinant solid phase immunoassay utilizing SH2 as the capture antibody and SH1 as the detecting antibody allowed direct determination of Le^x levels in sera. By the use of this direct assay, the levels of serum Le^x were found to increase in association with the progression of colorectal cancer (Dukes A to D). The percentage of detectability in sera from colon cancer patients was as follows: Dukes A, 20%; Dukes B, 45%; Dukes C, 67%; and Dukes D, 74%. The levels of serum Le^x were also of prognostic value in Dukes C cancer patients after surgery and during postoperative follow-up.

¹ This study was supported by funds from The Biomembrane Institute, Jenny Vissing, Lundbeck Fonden, and Statens Sundhedsvidenskabelige Forskningsråd (to H.C.).

² To whom requests for reprints should be addressed, at 201 Elliott Ave. W. Seattle, WA 98119.

Received 3/30/89. Revised 8/18/89. Revised 11/20/89. Accepted 11/22/89.

This article has been cited by other articles:

				A. Varki Trousseau's syndrome: multiple definitions and multiple mechanisms Blood, September 15, 2007; 110(6): 1723 - 1729. [Abstract] [Full Text] [PDF]

				M. G. Wahrenbrock and A. Varki Multiple Hepatic Receptors Cooperate to Eliminate Secretory Mucins Aberrantly Entering the Bloodstream: Are Circulating Cancer Mucins the "Tip of the Iceberg"? Cancer Res., February 15, 2006; 66(4): 2433 - 2441. [Abstract] [Full Text] [PDF]

				H Satoh, H Ishikawa, Y T Yamashita, M Ohtsuka, and K Sekizawa Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis Thorax, March 1, 2002; 57(3): 263 - 266. [Abstract] [Full Text] [PDF]

				M. Phillips, E Nudelman, F. Gaeta, M Perez, A. Singhal, S Hakomori, and J. Paulson ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex Science, November 23, 1990; 250(4984): 1130 - 1132. [Abstract] [PDF]